1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE

Identification

Name
1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE
Accession Number
DB06869
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 479.012
Monoisotopic: 478.234683335
Chemical Formula
C24H35ClN4O4
InChI Key
BMHVHOJXEQTIEA-SIKLNZKXSA-N
InChI
InChI=1S/C24H35ClN4O4/c1-2-27-21(30)15-33-20-11-10-18(25)13-17(20)14-28-23(31)19-9-6-12-29(19)24(32)22(26)16-7-4-3-5-8-16/h10-11,13,16,19,22H,2-9,12,14-15,26H2,1H3,(H,27,30)(H,28,31)/t19-,22+/m0/s1
IUPAC Name
(2S)-1-[(2R)-2-amino-2-cyclohexylacetyl]-N-({5-chloro-2-[(ethylcarbamoyl)methoxy]phenyl}methyl)pyrrolidine-2-carboxamide
SMILES
[H][C@@](N)(C1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=C(OCC(=O)NCC)C=CC(Cl)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProthrombinNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
448677
PubChem Substance
99443340
ChemSpider
395405
BindingDB
50066334
ChEMBL
CHEMBL42039
ZINC
ZINC000003831796
PDBe Ligand
177
PDB Entries
1ta6

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0218 mg/mLALOGPS
logP2.31ALOGPS
logP1.75ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.01ChemAxon
pKa (Strongest Basic)8.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area113.76 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity126.63 m3·mol-1ChemAxon
Polarizability51 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9867
Blood Brain Barrier-0.5715
Caco-2 permeable-0.6816
P-glycoprotein substrateSubstrate0.8152
P-glycoprotein inhibitor IInhibitor0.523
P-glycoprotein inhibitor IIInhibitor0.5801
Renal organic cation transporterNon-inhibitor0.6701
CYP450 2C9 substrateNon-substrate0.8511
CYP450 2D6 substrateNon-substrate0.7851
CYP450 3A4 substrateSubstrate0.6014
CYP450 1A2 substrateNon-inhibitor0.7708
CYP450 2C9 inhibitorInhibitor0.5327
CYP450 2D6 inhibitorNon-inhibitor0.5612
CYP450 2C19 inhibitorInhibitor0.7325
CYP450 3A4 inhibitorInhibitor0.6905
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8256
Ames testNon AMES toxic0.7986
CarcinogenicityNon-carcinogens0.7956
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.7122 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9316
hERG inhibition (predictor II)Inhibitor0.9028
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Proline and derivatives / Alpha amino acid amides / Pyrrolidinecarboxamides / Phenoxy compounds / Phenol ethers / N-acylpyrrolidines / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Tertiary carboxylic acid amides
show 8 more
Substituents
Alpha-dipeptide / Proline or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / Phenoxy compound / N-acylpyrrolidine / Phenol ether / Pyrrolidine-2-carboxamide / Pyrrolidine carboxylic acid or derivatives / Alkyl aryl ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Prothrombin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Thrombospondin receptor activity
Specific Function
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name
F2
Uniprot ID
P00734
Uniprot Name
Prothrombin
Molecular Weight
70036.295 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:17 / Updated on March 01, 2020 19:47

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates